GlassScriptPhysician profile
Dianne S Baldwin
NPI 1134221997
$5,119.80
in general payments reported to CMS, 2019-2025
32 companies · $818 in 2025
The $818 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $805 · 2022: $1,257 · 2023: $1,234 · 2024: $1,005 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,057.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $703.99 | 2021-2025 | Gallant, Jot Dx, Aveir |
| Merck Sharp & Dohme LLC | $479.65 | 2021-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $462.97 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $377.50 | 2021-2025 | |
| Boston Scientific Corporation | $376.66 | 2021-2024 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.97 | 2021-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $285.49 | 2021-2024 | Xarelto |
| Amgen INC. | $278.87 | 2021-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $261.44 | 2023-2025 | Camzyos, Eliquis |
| Pfizer INC. | $197.47 | 2021-2025 | |
| Esperion Therapeutics, INC. | $192.02 | 2021-2025 | Nexletol |
| Cvrx, INC. | $164.46 | 2022-2025 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $158.13 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $134.54 | 2021-2025 | Lifevest |
| Biotronik INC. | $123.02 | 2023-2024 | Biomonitor |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $88.59 | 2021-2024 | Farxiga |
| W. L. Gore & Associates, INC. | $64.19 | 2023-2024 | Excluder Conformable Aaa Endoprosthesis With Active Control, Gore Excluder Iliac Branch Endoprosthesis |
| Medtronic, INC. | $63.33 | 2021-2023 | Micra |
| Philips North America LLC | $57.43 | 2024-2025 | (Cm9) Amb Mon & Diag Und, Ecc Solutions, (Am5) Lead Management |
| Lexicon Pharmaceuticals, INC. | $48.16 | 2023 | Inpefa |
| Cardiva Medical, INC. | $47.65 | 2022-2024 | Optowire |
| Bridgebio Pharma, INC. | $44.77 | 2025 | Attruby |
| Scpharmaceuticals INC. | $38.40 | 2024-2025 | |
| Baxter Healthcare | $28.33 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Alnylam Pharmaceuticals INC. | $25.82 | 2023 | Onpattro |
| Kestra Medical Technology Services, INC. | $23.48 | 2023 | Assure Wcd |
| Amarin Pharma, INC. | $20.59 | 2021 | |
| Stryker Corporation | $20.06 | 2025 | Artix Mt |
| Abiomed | $18.13 | 2022 | |
| Chiesi USA, INC. | $15.32 | 2022 | |
| Angiodynamics, INC. | $14.97 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.40 | 2023 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dianne Baldwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.